Document Detail


Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
MedLine Citation:
PMID:  18670224     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess hematologic and hepatic toxicities associated with in utero and breastfeeding exposure to maternal highly active antiretroviral therapy (HAART) among infants in Botswana.
DESIGN: A nested cohort study within a randomized clinical trial (the Mashi Study). Laboratory toxicities among infants born to women who initiated HAART before delivery were compared with toxicities among those born to women who received zidovudine and a single dose of nevirapine or placebo in labor. Infants were randomized to breastfeed with extended zidovudine or to formula-feed.
METHODS: Hemoglobin concentrations, absolute neutrophil and platelet counts, and alanine aminotransferase and aspartate aminotransferase levels were recorded from birth to 7 months of age in infants. Grade 3 and 4 toxicities were compared by infant antiretroviral exposure status.
RESULTS: In-utero exposure to maternal HAART was associated with increased risk for neutropenia in infants up to 1 month of age; 21.7% of HAART-exposed infants were neutropenic, compared with 5.5% of the infants exposed to zidovudine (P < 0.01). However, neutropenia was no longer associated with antenatal exposure to HAART after 1 month of age. Postnatal exposure to HAART was not associated with hematologic or hepatic toxicities. Laboratory toxicities were clinically asymptomatic in all but one infant.
CONCLUSION: Exposure to maternal HAART in utero may increase the risk for infant neutropenia, particularly among breastfed infants, but the clinical significance of this finding is uncertain. The lack of association between exposure to HAART through breastfeeding and long-term toxicities in infants is reassuring but deserves study in larger cohorts.
Authors:
Woong Hwan Bae; Carolyn Wester; Laura M Smeaton; Roger L Shapiro; Shahin Lockman; Kenneth Onyait; Ibou Thior; Max Essex
Related Documents :
19772374 - Early exclusive breastfeeding and maternal attitudes towards infant feeding in a popula...
20929494 - The infant feeding intentions scale demonstrates construct validity and comparability i...
21254794 - Successful relactation--a case history.
12033074 - Cup or bottle for preterm infants: effects on oxygen saturation, weight gain, and breas...
22268644 - Time to consider a new treatment protocol for aggressive posterior retinopathy of prema...
3009074 - Congenital anomalies--retrospective and contemporary treatment.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  AIDS (London, England)     Volume:  22     ISSN:  1473-5571     ISO Abbreviation:  AIDS     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-01     Completed Date:  2008-09-24     Revised Date:  2011-05-05    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  England    
Other Details:
Languages:  eng     Pagination:  1633-40     Citation Subset:  IM; X    
Affiliation:
Harvard College, Harvard Faculty of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alanine Transaminase / blood
Anti-HIV Agents / adverse effects*,  therapeutic use
Anti-Retroviral Agents / adverse effects*,  therapeutic use
Antiretroviral Therapy, Highly Active / adverse effects
Aspartate Aminotransferases / blood
Biological Markers / blood
Botswana
Breast Feeding
Cohort Studies
Female
Follow-Up Studies
HIV Infections / drug therapy*,  immunology,  transmission*
HIV-1*
Hemoglobins / analysis
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical
Male
Neutropenia / etiology,  immunology
Nevirapine / adverse effects,  therapeutic use
Platelet Count
Pregnancy
Pregnancy Complications, Infectious / drug therapy*,  immunology
Prenatal Exposure Delayed Effects
Zidovudine / adverse effects,  therapeutic use
Grant Support
ID/Acronym/Agency:
K23 HD049292/HD/NICHD NIH HHS; K23 HD049292-03/HD/NICHD NIH HHS; R01 HD037793-05/HD/NICHD NIH HHS; R01 HD37793/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Anti-Retroviral Agents; 0/Biological Markers; 0/Hemoglobins; 129618-40-2/Nevirapine; 30516-87-1/Zidovudine; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.
Next Document:  HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural popula...